Cargando…
Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score
AIM: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. PATIENTS & METHODS: Initial treatment selection (AS vs treatment) and duration of A...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447833/ https://www.ncbi.nlm.nih.gov/pubmed/31483217 http://dx.doi.org/10.2217/pme-2019-0084 |
Sumario: | AIM: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. PATIENTS & METHODS: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. RESULTS: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. CONCLUSION: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment. |
---|